Immunomedics, Inc. Reports First Clinical Results of New Antibody-Directed Radiation Therapy for Colorectal Cancer

SAN ANTONIO, June 6, 2011 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that pretargeted radiation therapy with TF2, a humanized bispecific antibody owned by the Company, appears to be safe and tolerable in patients with advanced colorectal cancer. Results from the Phase I study were released by SNM at its 58th Annual Meeting Press Conference.